#China #biopharmaceuticals #Hangzhou #Clinical Trials #Tigermed

Tigermed Announces 2026 Interim Results

On August 28, 2026, Hangzhou Tigermed Consulting Co., Ltd. publicly disclosed its interim results for the year. The company, a dominant player in providing comprehensive research and development solutions in the biopharmaceutical and medical device sectors, demonstrated notable financial progress during the reporting period.

Financial Performance Highlights

In the first half of 2026, Tigermed's revenue soared to RMB 3,707.6 million, representing a robust year-over-year increase of 14.1%. The gross profit during the same period reached RMB 1,020.5 million, marking a 4.4% rise compared to the previous year. Adjusted net profit attributable to the owners saw an impressive jump of 31.8% year-over-year, tallying RMB 277.7 million.

Breaking down the revenue segments, the Clinical Trial Solutions sector outperformed with revenues of RMB 1,773.4 million, up 20.7% year-over-year. Meanwhile, the Clinical-related and Lab Services also showed growth, bringing in RMB 1,934.2 million, reflecting an 8.6% improvement. Domestic revenues in China reached RMB 2,106.1 million, increasing by 24.0%, while overseas revenue accounted for RMB 1,601.5 million, a modest rise of 3.2%.

Business Highlights and Strategic Collaborations

Tigermed's trajectory in the second quarter of 2026 highlighted a strong recovery post-pandemic, with the company signing several strategic cooperation agreements with notable industry players, including Hisun Pharmaceutical and Insilico Medicine. These partnerships focused on enhancing collaboration in clinical trials and early-stage research and development efforts. Additionally, the successful acquisitions of Teddy Laboratory and Shanghai Bioquick further solidify Tigermed's integrated capabilities, ranging from preclinical research to laboratory testing and the clinical supply chain.

In March 2026, the inauguration of Tigermed's new global headquarters and Tigermed Park in Hangzhou marked a significant milestone for the company, establishing a central hub for global operations and innovative development.

By June 30, 2026, Tigermed expanded its workforce to 11,984 employees globally, including 2,019 based overseas. The company played a crucial role in the development of 31 approved Class 1 new drugs in China in the first half of 2026, underscoring its influential position within the clinical research sector.

Expanding Clinical Trial Solutions

As of mid-2026, Tigermed was managing a total of 667 ongoing drug clinical research projects. The Regulatory Affairs division served a total of 1,014 clients, and the company added 28 new U.S. FDA Investigational New Drug (IND) projects. Notably, the medical device and in-vitro diagnostics (IVD) sectors achieved significant milestones, with over 600 professionals supporting the market introduction of five innovative medical device products.

The Pharmacovigilance unit also expanded, adding 141 new projects, while language services increased their clientele base and patent services were officially launched. New project orders for clinical site services improved by 13% year-over-year, marking a continuing trend of growth.

Commitment to Innovation and Technology

Tigermed is actively advancing its digital and intelligent innovation agendas by integrating Artificial Intelligence into clinical research workflows. The establishment of an intelligent clinical research platform centers around decentralized clinical trials (DCTs), AI large language models, and data visualization, which has improved operational efficiencies.

The firm has taken significant strides with its SAP (Statistical Analysis Plan) system, which has now moved into commercial operation. In the first half of 2026, Tigermed launched 30 new DCT projects, and revenues from clinical trials incorporating DCT elements surpassed RMB 300 million, indicating a strong market demand for these services.

Together with the China Society for Drug Regulation, Tigermed co-published a longitudinal survey report on DCT industry practices, emphasizing its commitment to research and development excellence.

Perspectives from Management

Dr. Xiaoping Ye, Tigermed’s Co-founder and Chairman, expressed optimism about the biopharmaceutical landscape in H1 2026, citing increased collaboration and R&D investments as driving factors behind the company’s success. Furthermore, both Ms. Xiaochun Cao and Zengyu (Michael) Wen reinforced the necessity for sustained growth, enhanced global competitiveness, and the ongoing integration of digital technologies in their operational strategies.

In summary, Tigermed's interim results for 2026 reveal a company that is not only navigating the challenges posed by the global healthcare environment but is also positioning itself as a leader within the industry through innovation, strategic partnerships, and an unwavering commitment to quality.